Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity

American Journal of Obstetrics and Gynecology

Volumn 217, Issue 3, 2017, Pages 282-302

  Romero, Roberto ^a,b,c,d   Erez, Offer ^a,d,e   Hüttemann, Maik ^d   Maymon, Eli ^a,d,e   Panaitescu, Bogdan ^a,d   Conde Agudelo, Agustin ^a   Pacora, Percy ^a,d   Yoon, Bo Hyun ^f   Grossman, Lawrence I ^d  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^f Seoul National University College of Medicine   (South Korea)

Author keywords

fms like tyrosine kinase 1 (sFlt 1); insulin resistance; large for gestational age (LGA); macrosomia; mitochondria; mTOR; nutritional sensing; obesity; placental growth factor (PlGF); soluble endoglin (sEng); soluble vascular endothelial growth factor receptor 1 (sVEGFR 1)

Indexed keywords

ACETYLSALICYLIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; VASCULOTROPIN RECEPTOR 1; ANTIDIABETIC AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

AGING; CANCER PREVENTION; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ERYTHEMA; FETUS GROWTH; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; LARGE FOR GESTATIONAL AGE; MALIGNANT NEOPLASM; MATERNAL HYPERTENSION; MOLECULAR WEIGHT; NAUSEA; NONHUMAN; NUTRIENT; NUTRITIONAL STATUS; OBESITY; PLACENTA; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; DIABETES, GESTATIONAL; FEMALE; FETOMATERNAL TRANSFUSION; FETUS DEVELOPMENT; LONGEVITY; MATERNAL NUTRITION; METABOLISM; NEOPLASMS; PRE-ECLAMPSIA; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DIABETES, GESTATIONAL; FEMALE; FETAL DEVELOPMENT; HUMANS; HYPOGLYCEMIC AGENTS; LONGEVITY; MATERNAL NUTRITIONAL PHYSIOLOGICAL PHENOMENA; MATERNAL-FETAL EXCHANGE; METFORMIN; NEOPLASMS; PRE-ECLAMPSIA; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOR SERINE-THREONINE KINASES;

EID: 85028557487     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2017.06.003     Document Type: Review

References (278)

1. Onken, B., Driscoll, M., Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PloS One, 5, 2010, e8758.
2. Cabreiro, F., Au, C., Leung, K.Y., et al. Metformin retards aging in C elegans by altering microbial folate and methionine metabolism. Cell 153 (2013), 228–239.
3. Martin-Montalvo, A., Mercken, E.M., Mitchell, S.J., et al. Metformin improves healthspan and lifespan in mice. Nat Commun, 4, 2013, 2192.
4. De Haes, W., Frooninckx, L., Van Assche, R., et al. Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2. Proc Natl Acad Sci U S A 111 (2014), E2501–E2509.
5. Crandall J. Metformin in Longevity Study (MILES). Clinical Trial.gov., 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT02432287.
6. Barzilai, N., Crandall, J.P., Kritchevsky, S.B., Espeland, M.A., Metformin as a tool to target aging. Cell Metab 23 (2016), 1060–1065.
7. Zhang, Z.J., Bi, Y., Li, S., et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis. Am J Epidemiol 180 (2014), 11–14.
8. Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G.F., Pellegrini, F., Nicolucci, A., Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PloS One, 8, 2013, e71583.
9. Wang, Z., Lai, S.T., Xie, L., et al. Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 106 (2014), 19–26.
10. Wu, L., Zhu, J., Prokop, L.J., Murad, M.H., Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-analysis of 265 studies. Scientific Rep, 5, 2015, 10147.
11. Victor, V.M., Rovira-Llopis, S., Banuls, C., et al. Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients. Atherosclerosis 242 (2015), 167–173.
12. Tan, X., Li, S., Chang, Y., et al. Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. Clin Invest Med 39 (2016), E120–E131.
13. Feng, L., Lin, X.F., Wan, Z.H., Hu, D., Du, Y.K., Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol 31 (2015), 833–839.
14. Brock, B., Smidt, K., Ovesen, P., Schmitz, O., Rungby, J., Is metformin therapy for polycystic ovary syndrome safe during pregnancy?. Basic Clin Pharmacol toxicol 96 (2005), 410–412.
15. Crowley, M.J., Diamantidis, C.J., McDuffie, J.R., et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 166 (2017), 191–200.
16. Nath, N., Khan, M., Paintlia, M.K., Singh, I., Hoda, M.N., Giri, S., Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol 182 (2009), 8005–8014.
17. Negrotto, L., Farez, M.F., Correale, J., Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol 73 (2016), 520–528.
18. Takiyama, Y., Harumi, T., Watanabe, J., et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1alpha expression and oxygen metabolism. Diabetes 60 (2011), 981–992.
19. Bhat, A., Sebastiani, G., Bhat, M., Systematic review: preventive and therapeutic applications of metformin in liver disease. World J Hepatol 7 (2015), 1652–1659.
20. Brownfoot, F.C., Hastie, R., Hannan, N.J., et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol 214 (2016), 356.e1–356.e15.
21. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in Pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 122 (2013), 1122–1131.
22. Witters, L.A., The blooming of the French lilac. J Clin Invest 108 (2001), 1105–1107.
23. Bailey, C.J., Turner, R.C., Metformin. N Engl J Med 334 (1996), 574–579.
24. Bailey, C.J., Day, C., Metformin: its botanical background. Pract Diabetes Int 21 (2004), 115–117.
25. Watanabe, C., Studies in the metabolic changes induced by administration of guanidine bases. J Biol Chem 33 (1918), 253–265.
26. Sterne, J., Pharmacology and mode of action of the hypoglycaemic guanidine derivatives. Campbell, G.D., (eds.) Oral hypoglycaemic agents: pharmacology and therapeutics, 1969, Academic Press, London, UK, 193–245.
27. Muller, H., Rheinwein, H., Pharmacology of galegin. Arch Expll Path Pharm 125 (1927), 212–228.
28. Simonnet, H., Tanret, G., [Sur les propietes hypoglycemiantes du sulfate de galegine.]. Bull Soc Chim Biol Paris, 8, 1927.
29. Nattrass, M., Alberti, K.G., Biguanides. Diabetologia 14 (1978), 71–74.
30. Paulesco, N., [Recherches sur le role du pancreas dans l'assimilation nutritive.]. Arch Int Physiol 17 (1921), 85–109.
31. Banting, F.G., Best, C.H., Collip, J.B., Campbell, W.R., Fletcher, A.A., Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 12 (1922), 141–146.
32. Sterne, J., [Treatment of diabetes mellitus with N,N-dimethylguanylguanidine (LA. 6023, glucophage)]. Therapie 14 (1959), 625–630.
33. Bernier, G.M., Miller, M., Springate, C.S., Lactic acidosis and phenformin hydrochloride. JAMA 184 (1963), 43–46.
34. Ewy, G.A., Pabico, R.C., Maher, J.F., Mintz, D.H., Lactate acidosis associated with phenformin therapy and localized tissue hypoxia: report of a case treated by hemodialysis. Ann Intern Med 59 (1963), 878–883.
35. Tranquada, R.E., Bernstein, S., Martin, H.E., Irreversible lactic acidosis associated with phenformine therapy: report of three cases. JAMA 184 (1963), 37–42.
36. Davidson, M.B., Bozarth, W.R., Challoner, D.R., Goodner, C.J., Phenformin, hypoglycemia and lactic acidosis: report of attempted suicide. N Engl J Med 275 (1966), 886–888.
37. Proctor, D.W., Stowers, J.M., Fatal lactic acidosis after an overdose of phenformin. Br Med J, 4, 1967, 216.
38. Shirriffs, G.G., Bewsher, P.D., Hypothermia, abdominal pain, and lactic acidosis in phenformin-treated diabetic. Br Med J, 3, 1970, 506.
39. Nathan, D.M., Buse, J.B., Davidson, M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32 (2009), 193–203.
40. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38 (2015), 140–149.
41. American Diabetes Association. 4. Prevention or delay of type 2 diabetes. Diabetes Care 39:suppl1 (2016), S36–S38.
42. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol 3 (2015), 866–875.
43. Knowler, W.C., Barrett-Connor, E., Fowler, S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002), 393–403.
44. Natali, A., Ferrannini, E., Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 49 (2006), 434–441.
45. Foretz, M., Guigas, B., Bertrand, L., Pollak, M., Viollet, B., Metformin: from mechanisms of action to therapies. Cell Metab 20 (2014), 953–966.
46. Viollet, B., Guigas, B., Sanz Garcia, N., Leclerc, J., Foretz, M., Andreelli, F., Cellular and molecular mechanisms of metformin: an overview. Clin Sci 122 (2012), 253–270.
47. Coetzee, E.J., Jackson, W.P., Metformin in management of pregnant insulin-independent diabetics. Diabetologia 16 (1979), 241–245.
48. Coetzee, E.J., Jackson, W.P., Diabetes newly diagnosed during pregnancy: a 4-year study at Groote Schuur Hospital. S Afr Med J 56 (1979), 467–475.
49. Jackson, W.P., Coetzee, E.J., Side-effects of metformin. S Afr Med J 56 (1979), 1113–1114.
50. Coetzee, E.J., Jackson, W.P., Pregnancy in established non-insulin-dependent diabetics: a five-and-a-half year study at Groote Schuur Hospital. S Afr Med J 58 (1980), 795–802.
51. Elliott, B.D., Langer, O., Schuessling, F., Human placental glucose uptake and transport are not altered by the oral antihyperglycemic agent metformin. Am J Obstet Gynecol 176 (1997), 527–530.
52. Simmons, D., Walters, B.N., Rowan, J.A., McIntyre, H.D., Metformin therapy and diabetes in pregnancy. Med J Aust 180 (2004), 462–464.
53. Vanky, E., Salvesen, K.A., Heimstad, R., Fougner, K.J., Romundstad, P., Carlsen, S.M., Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod 19 (2004), 1734–1740.
54. Coustan, D.R., Pharmacological management of gestational diabetes: an overview. Diabetes Care 30:suppl2 (2007), S206–S208.
55. Ecker, J.L., Greene, M.F., Gestational diabetes: setting limits, exploring treatments. N Engl J Med 358 (2008), 2061–2063.
56. Rowan, J.A., Hague, W.M., Gao, W., Battin, M.R., Moore, M.P., Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 358 (2008), 2003–2015.
57. Paglia, M.J., Coustan, D.R., The use of oral antidiabetic medications in gestational diabetes mellitus. Curr Diabetes Rep 9 (2009), 287–290.
58. Glueck, C.J., Goldenberg, N., Streicher, P., Wang, P., The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. Expert Opin Pharmacother 3 (2002), 1557–1568.
59. Glueck, C.J., Wang, P., Kobayashi, S., Phillips, H., Sieve-Smith, L., Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 77 (2002), 520–525.
60. Glueck, C.J., Goldenberg, N., Streicher, P., Wang, P., Metformin and gestational diabetes. Current Diabetes Rep 3 (2003), 303–312.
61. Homko, C.J., Reece, E.A., Insulins and oral hypoglycemic agents in pregnancy. J Matern Fetal Neonatal Med 19 (2006), 679–686.
62. Metzger, B.E., Diet and medical therapy in the optimal management of gestational diabetes mellitus. Nestle Nutr Workshop Ser Clin Perform programme 11 (2006), 155–165 discussion 65-9.
63. Eyal, S., Easterling, T.R., Carr, D., et al. Pharmacokinetics of metformin during pregnancy. Drug Metabo Dispos 38 (2010), 833–840.
64. Ballas, J., Moore, T.R., Ramos, G.A., Management of diabetes in pregnancy. Current Diabetes Rep 12 (2012), 33–42.
65. Langer, O., Oral hypoglycemic agents: do the ends justify the means? Matern Health. Neonatol Perinatol, 1, 2015, 19.
66. Ma, R.C., Schmidt, M.I., Tam, W.H., McIntyre, H.D., Catalano, P.M., Clinical management of pregnancy in the obese mother: before conception, during pregnancy, and post partum. Lancet Diabetes Endocrinol 4 (2016), 1037–1049.
67. Magon, N., Seshiah, V., Gestational diabetes mellitus: non-insulin management. Indian J Endocrinol Metab 15 (2011), 284–293.
68. Kampmann, U., Madsen, L.R., Skajaa, G.O., Iversen, D.S., Moeller, N., Ovesen, P., Gestational diabetes: a clinical update. World J Diabetes 6 (2015), 1065–1072.
69. DeFronzo, R.A., Goodman, A.M., Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333 (1995), 541–549.
70. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 854–865.
71. Ijas, H., Vaarasmaki, M., Morin-Papunen, L., et al. Metformin should be considered in the treatment of gestational diabetes: a prospective randomised study. BJOG 118 (2011), 880–885.
72. Moore, L.E., Briery, C.M., Clokey, D., et al. Metformin and insulin in the management of gestational diabetes mellitus: preliminary results of a comparison. J Reprod Med 52 (2007), 1011–1015.
73. Niromanesh, S., Alavi, A., Sharbaf, F.R., Amjadi, N., Moosavi, S., Akbari, S., Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial. Diabetes Res Clin Pract 98 (2012), 422–429.
74. Tertti, K., Ekblad, U., Koskinen, P., Vahlberg, T., Ronnemaa, T., Metformin vs insulin in gestational diabetes: a randomized study characterizing metformin patients needing additional insulin. Diabetes Obes Metab 15 (2013), 246–251.
75. Gui, J., Liu, Q., Feng, L., Metformin vs insulin in the management of gestational diabetes: a meta-analysis. PloS One, 8, 2013, e64585.
76. Feng, Y., Yang, H., Metformin: a potentially effective drug for gestational diabetes mellitus: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 30 (2017), 1874–1881.
77. Butalia, S., Gutierrez, L., Lodha, A., Aitken, E., Zakariasen, A., Donovan, L., Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. Diabetic Med 34 (2017), 27–36.
78. Hickman, M.A., McBride, R., Boggess, K.A., Strauss, R., Metformin compared with insulin in the treatment of pregnant women with overt diabetes: a randomized controlled trial. Am J Perinatol 30 (2013), 483–490.
79. Spaulonci, C.P., Bernardes, L.S., Trindade, T.C., Zugaib, M., Francisco, R.P., Randomized trial of metformin vs insulin in the management of gestational diabetes. Am J Obstet Gynecol 209 (2013), 34.e1–34.e7.
80. Ibrahim, M.I., Hamdy, A., Shafik, A., Taha, S., Anwar, M., Faris, M., The role of adding metformin in insulin-resistant diabetic pregnant women: a randomized controlled trial. Arch Gynecol Obstet 289 (2014), 959–965.
81. Ruholamin, S., Eshaghian, S., Allame, Z., Neonatal outcomes in women with gestational diabetes mellitus treated with metformin in compare with insulin: a randomized clinical trial. J res med sci 19 (2014), 970–975.
82. Ainuddin, J., Karim, N., Hasan, A.A., Naqvi, S.A., Metformin versus insulin treatment in gestational diabetes in pregnancy in a developing country: a randomized control trial. Diabetes Res Clin Pract 107 (2015), 290–299.
83. Refuerzo, J.S., Gowen, R., Pedroza, C., Hutchinson, M., Blackwell, S.C., Ramin, S., A pilot randomized, controlled trial of metformin versus insulin in women with type 2 diabetes mellitus during pregnancy. American J Perinatol 30 (2015), 163–170.
84. Rodgers, G.M., Taylor, R.N., Roberts, J.M., Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. Am J Obstet Gynecol 159 (1988), 908–914.
85. Roberts, J.M., Taylor, R.N., Musci, T.J., Rodgers, G.M., Hubel, C.A., McLaughlin, M.K., Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 161 (1989), 1200–1204.
86. Myatt, L., Webster, R.P., Vascular biology of preeclampsia. J Thromb Haemost 7 (2009), 375–384.
87. Myatt, L., Kossenjans, W., Sahay, R., Eis, A., Brockman, D., Oxidative stress causes vascular dysfunction in the placenta. J Matern Fetal Med 9 (2000), 79–82.
88. Hubel, C.A., Kozlov, A.V., Kagan, V.E., et al. Decreased transferrin and increased transferrin saturation in sera of women with preeclampsia: implications for oxidative stress. Am J Obstet Gynecol 175 (1996), 692–700.
89. Many, A., Hubel, C.A., Roberts, J.M., Hyperuricemia and xanthine oxidase in preeclampsia, revisited. Am J Obstet Gynecol 174 (1996), 288–291.
90. Burton, G.J., Jauniaux, E., Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig 11 (2004), 342–352.
91. Burton, G.J., Yung, H.W., Cindrova-Davies, T., Charnock-Jones, D.S., Placental endoplasmic reticulum stress and oxidative stress in the pathophysiology of unexplained intrauterine growth restriction and early onset preeclampsia. Placenta 30:supplA (2009), S43–S48.
92. Myatt, L., Review: reactive oxygen and nitrogen species and functional adaptation of the placenta. Placenta 31:suppl (2010), S66–S69.
93. Burton, G.J., Jauniaux, E., Oxidative stress. Best Pract Res Clin Obstet Gynaecol 25 (2011), 287–299.
94. Ilekis, J.V., Tsilou, E., Fisher, S., et al. Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Am J Obstet Gynecol 215:suppl (2016), S1–S46.
95. Chiswick, C., Reynolds, R.M., Denison, F., et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 3 (2015), 778–786.
96. Syngelaki, A., Nicolaides, K.H., Balani, J., et al. Metformin versus placebo in obese pregnant women without diabetes mellitus. N Engl J Med 374 (2016), 434–443.
97. Cramer, J.A., Spilker, B., Patient compliance in medical practice and clinical trials. 1991, Raven Press, New York, 387–392.
98. Cramer, J.A., Effect of partial compliance on cardiovascular medication effectiveness. Heart 88 (2002), 203–206.
99. Cramer, J., Rosenheck, R., Kirk, G., Krol, W., Krystal, J., Group VANS. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 6 (2003), 566–573.
100. Cramer, J.A., Roy, A., Burrell, A., et al. Medication compliance and persistence: terminology and definitions. Value Health 11 (2008), 44–47.
101. Shingler, S.L., Bennett, B.M., Cramer, J.A., Towse, A., Twelves, C., Lloyd, A.J., Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model. Curr Med Res Opin 30 (2014), 2329–2341.
102. Romero, R., Lockwood, C., Oyarzun, E., Hobbins, J.C., Toxemia: new concepts in an old disease. Semin Perinatol 12 (1988), 302–323.
103. Sibai, B., Dekker, G., Kupferminc, M., Pre-eclampsia. Lancet 365 (2005), 785–799.
104. Young, B.C., Levine, R.J., Karumanchi, S.A., Pathogenesis of preeclampsia. Ann Rev Pathol 5 (2010), 173–192.
105. Brosens, I., Pijnenborg, R., Vercruysse, L., Romero, R., The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol 204 (2011), 193–201.
106. Maynard, S.E., Karumanchi, S.A., Angiogenic factors and preeclampsia. Semin Nephrol 31 (2011), 33–46.
107. Redman, C.W., Preeclampsia: a multi-stress disorder. Rev Med Interne 32:suppl1 (2011), S41–S44.
108. Tranquilli, A.L., Landi, B., Giannubilo, S.R., Sibai, B.M., Preeclampsia: no longer solely a pregnancy disease. Pregnancy Hypertens 2 (2012), 350–357.
109. Staff, A.C., Benton, S.J., von Dadelszen, P., et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension 61 (2013), 932–942.
110. Staff, A.C., Dechend, R., Redman, C.W., Review: preeclampsia, acute atherosis of the spiral arteries and future cardiovascular disease: two new hypotheses. Placenta 34:suppl (2013), S73–S78.
111. Chaiworapongsa, T., Chaemsaithong, P., Korzeniewski, S.J., Yeo, L., Romero, R., Pre-eclampsia part 2: prediction, prevention and management. Nat Rev Nephrol 10 (2014), 531–540.
112. Roberts, J.M., Pathophysiology of ischemic placental disease. Semin Perinatol 38 (2014), 139–145.
113. Redman, C.W., Staff, A.C., Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol 213:suppl4 (2015), S9.e1–S9.e11.
114. Hod, T., Cerdeira, A.S., Karumanchi, S.A., Molecular mechanisms of preeclampsia. Cold Spring Harbor Perspect Med., 5(10), 2015.
115. Myatt, L., Roberts, J.M., Preeclampsia: syndrome or disease?. Current Hypertens Rep, 17, 2015, 83.
116. Fisher, S.J., Why is placentation abnormal in preeclampsia?. Am J Obstet Gynecol 213:suppl4 (2015), S115–S122.
117. Sircar, M., Thadhani, R., Karumanchi, S.A., Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens 24 (2015), 131–138.
118. Korzeniewski, S.J., Romero, R., Chaiworapongsa, T., et al. Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study. Am J Obstet Gynecol 214 (2016), 629.e1–629.e17.
119. Chaiworapongsa, T., Romero, R., Espinoza, J., et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: Young Investigator Award. Am J Obstet Gynecol 190 (2004), 1541–1550.
120. Chaiworapongsa, T., Romero, R., Kim, Y.M., et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 17 (2005), 3–18.
121. Bujold, E., Romero, R., Chaiworapongsa, T., et al. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. J Matern Fetal Neonatal Med 18 (2005), 9–16.
122. Park, C.W., Park, J.S., Shim, S.S., Jun, J.K., Yoon, B.H., Romero, R., An elevated maternal plasma, but not amniotic fluid, soluble fms-like tyrosine kinase-1 (sFlt-1) at the time of mid-trimester genetic amniocentesis is a risk factor for preeclampsia. Am J Obstet Gynecol 193 (2005), 984–989.
123. Espinoza, J., Romero, R., Nien, J.K., et al. A role of the anti-angiogenic factor sVEGFR-1 in the ‘mirror syndrome’ (Ballantyne's syndrome). J Matern Fetal Neonatal Med 19 (2006), 607–613.
124. Venkatesha, S., Toporsian, M., Lam, C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12 (2006), 642–649.
125. Levine, R.J., Lam, C., Qian, C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355 (2006), 992–1005.
126. Espinoza, J., Romero, R., Nien, J.K., et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 196 (2007), 326.e1–326.e13.
127. Chaiworapongsa, T., Espinoza, J., Gotsch, F., et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med 21 (2008), 25–40.
128. Erez, O., Romero, R., Espinoza, J., et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 21 (2008), 279–287.
129. Romero, R., Nien, J.K., Espinoza, J., et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 21 (2008), 9–23.
130. Than, N.G., Romero, R., Hillermann, R., Cozzi, V., Nie, G., Huppertz, B., Prediction of preeclampsia: a workshop report. Placenta 29:supplA (2008), S83–S85.
131. Toft, J.H., Lian, I.A., Tarca, A.L., et al. Whole-genome microarray and targeted analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PlGF) in placentas from pre-eclamptic and small-for-gestational-age pregnancies. J Matern Fetal Neonatal Med 21 (2008), 267–273.
132. Kusanovic, J.P., Romero, R., Chaiworapongsa, T., et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 22 (2009), 1021–1038.
133. Chaiworapongsa, T., Romero, R., Savasan, Z.A., et al. Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 24 (2011), 1187–1207.
134. Romero, R., Chaiworapongsa, T., Erez, O., et al. An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study. J Matern Fetal Neonatal Med 23 (2010), 1384–1399.
135. Vaisbuch, E., Whitty, J.E., Hassan, S.S., et al. Circulating angiogenic and antiangiogenic factors in women with eclampsia. Am J Obstet Gynecol 204 (2011), 152.e1–152.e9.
136. Soto, E., Romero, R., Kusanovic, J.P., et al. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med 25 (2012), 498–507.
137. Chaiworapongsa, T., Romero, R., Korzeniewski, S.J., et al. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol 208 (2013), 287.e1–287.e15.
138. Chaiworapongsa, T., Romero, R., Korzeniewski, S.J., et al. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med 27 (2014), 132–144.
139. Adekola, H., Romero, R., Chaemsaithong, P., et al. Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes. J Matern Fetal Neonatal Med 28 (2015), 1621–1632.
140. Faupel-Badger, J.M., McElrath, T.F., Lauria, M., et al. Maternal circulating angiogenic factors in twin and singleton pregnancies. Am J Obstet Gynecol 212 (2015), 636.e1–636.e8.
141. Szalai, G., Romero, R., Chaiworapongsa, T., et al. Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice. PloS One, 10, 2015, e0119547.
142. Chaiworapongsa, T., Romero, R., Whitten, A.E., et al. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia. J Matern Fetal Neonatal Med 29 (2016), 1214–1228.
143. Chaiworapongsa, T., Chaemsaithong, P., Yeo, L., Romero, R., Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol 10 (2014), 466–480.
144. Ogge, G., Romero, R., Kusanovic, J.P., et al. Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice. J Matern Fetal Neonatal Med 23 (2010), 820–827.
145. Powers, R.W., Jeyabalan, A., Clifton, R.G., et al. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PloS One, 5, 2010, e13263.
146. Rana, S., Powe, C.E., Salahuddin, S., et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125 (2012), 911–919.
147. Baltajian, K., Bajracharya, S., Salahuddin, S., et al. Sequential plasma angiogenic factors levels in women with suspected preeclampsia. Am J Obstet Gynecol 215 (2016), 89.e1–89.e10.
148. Karumanchi, S.A., Angiogenic factors in preeclampsia: from diagnosis to therapy. Hypertension 67 (2016), 1072–1079.
149. Holme, A.M., Roland, M.C., Henriksen, T., Michelsen, T.M., In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies. Am J Obstet Gynecol 215 (2016), 782.e1–782.e9.
150. Malshe, A.K., Sibai, B.M., Angiogenic and antiangiogenic markers for prediction and risk classification of preeclampsia. Clin Obstet Gynecol 60 (2017), 134–140.
151. Levine, R.J., Maynard, S.E., Qian, C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350 (2004), 672–683.
152. Lai, J., Garcia-Tizon Larroca, S., Peeva, G., Poon, L.C., Wright, D., Nicolaides, K.H., Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks’ gestation. Fetal Diagn Ther 35:4 (2014), 240–248.
153. Tsiakkas, A., Saiid, Y., Wright, A., Wright, D., Nicolaides, K.H., Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks’ gestation. Am J Obstet Gynecol 215 (2016), 87.e1–87.e17.
154. Lam, C., Lim, K.H., Karumanchi, S.A., Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 46 (2005), 1077–1085.
155. Gallo, D.M., Wright, D., Casanova, C., Campanero, M., Nicolaides, K.H., Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks’ gestation. Am J Obstet Gynecol 214 (2016), 619.e1–619.e17.
156. Moore Simas, T.A., Crawford, S.L., Solitro, M.J., Frost, S.C., Meyer, B.A., Maynard, S.E., Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 197 (2007), 244.e1–244.e8.
157. Stepan, H., Unversucht, A., Wessel, N., Faber, R., Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 49 (2007), 818–824.
158. Diab, A.E., El-Behery, M.M., Ebrahiem, M.A., Shehata, A.E., Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry. Int J Gynaecol Obstet 102 (2008), 146–151.
159. Stepan, H., Geipel, A., Schwarz, F., Kramer, T., Wessel, N., Faber, R., Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 198 (2008), 175.e1–175.e6.
160. Garovic, V.D., The role of angiogenic factors in the prediction and diagnosis of preeclampsia superimposed on chronic hypertension. Hypertension 59 (2012), 555–557.
161. Hagmann, H., Thadhani, R., Benzing, T., Karumanchi, S.A., Stepan, H., The promise of angiogenic markers for the early diagnosis and prediction of preeclampsia. Clin Chem 58 (2012), 837–845.
162. Holmes, V.A., Young, I.S., Patterson, C.C., et al. The role of angiogenic and antiangiogenic factors in the second trimester in the prediction of preeclampsia in pregnant women with type 1 diabetes. Diabetes Care 36 (2013), 3671–3677.
163. McElrath, T.F., Lim, K.H., Pare, E., et al. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol 207 (2012), 407.e1–407.e7.
164. Zeisler, H., Llurba, E., Chantraine, F., et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med 374 (2016), 13–22.
165. Myers, J.E., Kenny, L.C., McCowan, L.M., et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG 120 (2013), 1215–1223.
166. Poston, L., Prediction and diagnosis of pre-eclampsia; the scientific basis. Pregnancy Hypertens, 3, 2013, 57.
167. Verlohren, S., Stepan, H., Dechend, R., Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin Sci 122 (2012), 43–52.
168. Akolekar, R., Zaragoza, E., Poon, L.C., Pepes, S., Nicolaides, K.H., Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 32 (2008), 732–739.
169. Foidart, J.M., Munaut, C., Chantraine, F., Akolekar, R., Nicolaides, K.H., Maternal plasma soluble endoglin at 11-13 weeks’ gestation in pre-eclampsia. Ultrasound Obstet Gynecol 35 (2010), 680–687.
170. Crovetto, F., Figueras, F., Triunfo, S., et al. Added value of angiogenic factors for the prediction of early and late preeclampsia in the first trimester of pregnancy. Fetal Diagn Ther 35 (2014), 258–266.
171. Garcia-Tizon Larroca, S., Tayyar, A., Poon, L.C., Wright, D., Nicolaides, K.H., Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks’ gestation. Fetal Diagn Ther 36 (2014), 9–17.
172. Moore Simas, T.A., Crawford, S.L., Bathgate, S., et al. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women. J Matern Fetal Neonatal Med 27 (2014), 1038–1048.
173. Crovetto, F., Figueras, F., Triunfo, S., et al. First trimester screening for early and late preeclampsia based on maternal characteristics, biophysical parameters, and angiogenic factors. Prenatal Diagn 35 (2015), 183–191.
174. Widmer, M., Cuesta, C., Khan, K.S., et al. Accuracy of angiogenic biomarkers at 20weeks’ gestation in predicting the risk of pre-eclampsia: a WHO multicentre study. Pregnancy Hypertens 5 (2015), 330–338.
175. Di Martino, D., Cetin, I., Frusca, T., et al. Italian Advisory Board: sFlt-1/PlGF ratio and preeclampsia, state of the art and developments in diagnostic, therapeutic and clinical management. Eur J Obstet Gynecol Reprod Biol 206 (2016), 70–73.
176. Kienast, C., Moya, W., Rodriguez, O., Jijon, A., Geipel, A., Predictive value of angiogenic factors, clinical risk factors and uterine artery Doppler for pre-eclampsia and fetal growth restriction in second and third trimester pregnancies in an Ecuadorian population. J Matern Fetal Neonatal Med 29 (2016), 537–543.
177. Khalil, A., Maiz, N., Garcia-Mandujano, R., Penco, J.M., Nicolaides, K.H., Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia. Ultrasound Obstet Gynecol 47 (2016), 324–331.
178. Lai, J., Pinas, A., Poon, L.C., Agathokleous, M., Nicolaides, K.H., Maternal serum placental growth factor, pregnancy-associated plasma protein-a and free beta-human chorionic gonadotrophin at 30-33 weeks in the prediction of pre-eclampsia. Fetal Diagn Ther 33 (2013), 164–172.
179. Nucci, M., Poon, L.C., Demirdjian, G., Darbouret, B., Nicolaides, K.H., Maternal serum placental growth factor (PlGF) isoforms 1 and 2 at 11-13 weeks’ gestation in normal and pathological pregnancies. Fetal Diagn Ther 36 (2014), 106–116.
180. Maynard, S.E., Min, J.Y., Merchan, J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 (2003), 649–658.
181. Weinstein, L., Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 142 (1982), 159–167.
182. Romero, R., Vizoso, J., Emamian, M., et al. Clinical significance of liver dysfunction in pregnancy-induced hypertension. Am J Perinatol 5 (1988), 146–151.
183. Abildgaard, U., Heimdal, K., Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. Eur J Obstet Gynecol Reprod Biol 166 (2013), 117–123.
184. Szabo, S., Mody, M., Romero, R., et al. Activation of villous trophoblastic p38 and ERK1/2 signaling pathways in preterm preeclampsia and HELLP syndrome. Pathol Oncol Res 21 (2015), 659–668.
185. Weel, I.C., Baergen, R.N., Romao-Veiga, M., et al. Association between placental lesions, cytokines and angiogenic factors in pregnant women with preeclampsia. PloS One, 11, 2016, e0157584.
186. Ananth, C.V., Peltier, M.R., Chavez, M.R., Kirby, R.S., Getahun, D., Vintzileos, A.M., Recurrence of ischemic placental disease. Obstet Gynecol 110 (2007), 128–133.
187. Ananth, C.V., Peltier, M.R., Kinzler, W.L., Smulian, J.C., Vintzileos, A.M., Chronic hypertension and risk of placental abruption: is the association modified by ischemic placental disease?. Am J Obstet Gynecol 197 (2007), 273.e1–273.e7.
188. Ananth, C.V., Smulian, J.C., Vintzileos, A.M., Ischemic placental disease: maternal versus fetal clinical presentations by gestational age. J Matern Fetal Neonatal Med 23 (2010), 887–893.
189. Ananth, C.V., Vintzileos, A.M., Ischemic placental disease: epidemiology and risk factors. Eur J Obstet Gynecol Reprod Biol 159 (2011), 77–82.
190. Vince, G.S., Starkey, P.M., Austgulen, R., Kwiatkowski, D., Redman, C.W., Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia. Br J Obstet Gynaecol 102 (1995), 20–25.
191. Bartha, J.L., Romero-Carmona, R., Escobar-Llompart, M., Comino-Delgado, R., The relationships between leptin and inflammatory cytokines in women with pre-eclampsia. BJOG 108 (2001), 1272–1276.
192. Velzing-Aarts, F.V., Muskiet, F.A., van der Dijs, F.P., Duits, A.J., High serum interleukin-8 levels in afro-caribbean women with pre-eclampsia: relations with tumor necrosis factor-alpha, duffy negative phenotype and von Willebrand factor. Am j reprod immunol 48 (2002), 319–322.
193. Visser, W., Beckmann, I., Knook, M.A., Wallenburg, H.C., Soluble tumor necrosis factor receptor II and soluble cell adhesion molecule 1 as markers of tumor necrosis factor-alpha release in preeclampsia. Acta Obstet Gynecol Scand 81 (2002), 713–719.
194. Tosun, M., Celik, H., Avci, B., Yavuz, E., Alper, T., Malatyalioglu, E., Maternal and umbilical serum levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in normal pregnancies and in pregnancies complicated by preeclampsia. J Matern Fetal Neonatal Med 23 (2010), 880–886.
195. Szarka, A., Rigo, J. Jr., Lazar, L., Beko, G., Molvarec, A., Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol, 11, 2010, 59.
196. Torbergsen, T., Oian, P., Mathiesen, E., Borud, O., Pre-eclampsia: a mitochondrial disease?. Acta Obstet Gynecol Scand 68 (1989), 145–148.
197. Masoura, S., Makedou, K., Theodoridis, T., Kourtis, A., Zepiridis, L., Athanasiadis, A., The involvement of uric acid in the pathogenesis of preeclampsia. Curr Hypertens Rev 11 (2015), 110–115.
198. Shanklin, D.R., Sibai, B.M., Ultrastructural aspects of preeclampsia: II, mitochondrial changes. Am J Obstet Gynecol 163 (1990), 943–953.
199. Berkowitz, K., Monteagudo, A., Marks, F., Jackson, U., Baxi, L., Mitochondrial myopathy and preeclampsia associated with pregnancy. Am J Obstet Gynecol 162 (1990), 146–147.
200. Shi, Z., Long, W., Zhao, C., Guo, X., Shen, R., Ding, H., Comparative proteomics analysis suggests that placental mitochondria are involved in the development of pre-eclampsia. PloS One, 8, 2013, e64351.
201. Qiu, C., Hevner, K., Enquobahrie, D.A., Williams, M.A., A case-control study of maternal blood mitochondrial DNA copy number and preeclampsia risk. Int J Mol Epidemiol Genet 3 (2012), 237–244.
202. Bonney, E.A., Preeclampsia: a view through the danger model. J Reprod Immunol 76 (2007), 68–74.
203. Mando, C., De Palma, C., Stampalija, T., et al. Placental mitochondrial content and function in intrauterine growth restriction and preeclampsia. Am J Physiol Endocrinol Metab 306 (2014), E404–E413.
204. Zhu, X.M., Han, T., Sargent, I.L., Yin, G.W., Yao, Y.Q., Differential expression profile of microRNAs in human placentas from preeclamptic pregnancies vs normal pregnancies. Am J Obstet Gynecol 200 (2009), 661.e1–661.e7.
205. Pineles, B.L., Romero, R., Montenegro, D., et al. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol 196 (2007), 261.e1–261.e6.
206. Lee, D.C., Romero, R., Kim, J.S., et al. MiR-210 targets iron-sulfur cluster scaffold homologue in human trophoblast cell lines: siderosis of interstitial trophoblasts as a novel pathology of preterm preeclampsia and small-for-gestational-age pregnancies. Am J Pathol 179 (2011), 590–602.
207. Muralimanoharan, S., Maloyan, A., Mele, J., Guo, C., Myatt, L.G., Myatt, L., MIR-210 modulates mitochondrial respiration in placenta with preeclampsia. Placenta 33 (2012), 816–823.
208. Vishnyakova, P.A., Volodina, M.A., Tarasova, N.V., et al. Mitochondrial role in adaptive response to stress conditions in preeclampsia. Sci Rep, 6, 2016, 32410.
209. Bianco-Miotto, T., Blundell, C., Buckberry, S., et al. IFPA meeting 2015 workshop report I: placental mitochondrial function, transport systems and epigenetics. Placenta 48:suppl1 (2016), S3–S6.
210. Owen, M.R., Doran, E., Halestrap, A.P., Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348 (2000), 607–614.
211. Hur, K.Y., Lee, M.S., New mechanisms of metformin action: Focusing on mitochondria and the gut. J Diabetes Investig 6 (2015), 600–609.
212. Madiraju, A.K., Erion, D.M., Rahimi, Y., et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510 (2014), 542–546.
213. Selak, M.A., Armour, S.M., MacKenzie, E.D., et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7 (2005), 77–85.
214. Kanasaki, K., Palmsten, K., Sugimoto, H., et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 453 (2008), 1117–1121.
215. Tal, R., The role of hypoxia and hypoxia-inducible factor-1alpha in preeclampsia pathogenesis. Biol Reprod 87 (2012), 1–8.
216. Zhou, G., Myers, R., Li, Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108 (2001), 1167–1174.
217. Miller, R.A., Chu, Q., Xie, J., Foretz, M., Viollet, B., Birnbaum, M.J., Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494 (2013), 256–260.
218. Batandier, C., Guigas, B., Detaille, D., El-Mir, M.Y., Fontaine, E., Rigoulet, M., et al. The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr 38 (2006), 33–42.
219. Portela, L.V., Gnoatto, J., Brochier, A.W., et al. Intracerebroventricular metformin decreases body weight but has pro-oxidant effects and decreases survival. Neurochem Res 40 (2015), 514–523.
220. Blagosklonny, M.V., Hall, M.N., Growth and aging: a common molecular mechanism. Aging 1 (2009), 357–362.
221. Chantranupong, L., Wolfson, R.L., Sabatini, D.M., Nutrient-sensing mechanisms across evolution. Cell 161 (2015), 67–83.
222. Meier, U., Gressner, A.M., Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 50 (2004), 1511–1525.
223. Hopkins, M., Blundell, J.E., Energy balance, body composition, sedentariness and appetite regulation: pathways to obesity. Clin Sci 130 (2016), 1615–1628.
224. Hu, F., Xu, Y., Liu, F., Hypothalamic roles of mTOR complex I: integration of nutrient and hormone signals to regulate energy homeostasis. Am J Physiol Endocrinol Metabol 310 (2016), E994–E1002.
225. Jansson, T., Powell, T.L., Role of placental nutrient sensing in developmental programming. Clin Obstet Gynecol 56 (2013), 591–601.
226. Roos, S., Powell, T.L., Jansson, T., Placental mTOR links maternal nutrient availability to fetal growth. Biochem Soc Trans 37 (2009), 295–298.
227. Rosario, F.J., Kanai, Y., Powell, T.L., Jansson, T., Mammalian target of rapamycin signalling modulates amino acid uptake by regulating transporter cell surface abundance in primary human trophoblast cells. J Physiol 591 (2013), 609–625.
228. Vezina, C., Kudelski, A., Sehgal, S.N., Rapamycin (AY-22,989), a new antifungal antibiotic: I, taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 28 (1975), 721–726.
229. Lamming, D.W., Inhibition of the mechanistic target of rapamycin (mTOR)-rapamycin and beyond. Cold Spring Harbor Perspect Med, 6, 2016, a025924.
230. Zoncu, R., Efeyan, A., Sabatini, D.M., mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12 (2011), 21–35.
231. Hirota, Y., Cha, J., Yoshie, M., Daikoku, T., Dey, S.K., Heightened uterine mammalian target of rapamycin complex 1 (mTORC1) signaling provokes preterm birth in mice. Proc Natl Acad Sci U S A 108 (2011), 18073–18078.
232. Shimobayashi, M., Hall, M.N., Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 15 (2014), 155–162.
233. Kim, Y.C., Guan, K.L., MTOR: a pharmacologic target for autophagy regulation. J Clin Invest 125 (2015), 25–32.
234. Deng, W., Cha, J., Yuan, J., et al. P53 coordinates decidual sestrin 2/AMPK/mTORC1 signaling to govern parturition timing. J Clin Invest 126 (2016), 2941–2954.
235. Kennedy, B.K., Lamming, D.W., The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging. Cell Metab 23 (2016), 990–1003.
236. Xie, J., Wang, X., Proud, C.G., MTOR inhibitors in cancer therapy. F1000Res, 5, 2016, 2078.
237. Aylett, C.H., Sauer, E., Imseng, S., et al. Architecture of human mTOR complex 1. Science 351 (2016), 48–52.
238. Xu, S., Cai, Y., Wei, Y., MTOR signaling from cellular senescence to organismal aging. Aging Dis 5 (2014), 263–273.
239. Wei, Y., Zhang, Y.J., Cai, Y., Xu, M.H., The role of mitochondria in mTOR-regulated longevity. Biol Rev Camb Philos Soc 90 (2015), 167–181.
240. Lager, S., Powell, T.L., Regulation of nutrient transport across the placenta. J Pregnancy, 2012, 2012, 179827.
241. Fujita, D., Tanabe, A., Sekijima, T., et al. Role of extracellular signal-regulated kinase and AKT cascades in regulating hypoxia-induced angiogenic factors produced by a trophoblast-derived cell line. J Endocrinol 206 (2010), 131–140.
242. Nanovskaya, T.N., Nekhayeva, I.A., Patrikeeva, S.L., Hankins, G.D., Ahmed, M.S., Transfer of metformin across the dually perfused human placental lobule. Am J Obstet Gynecol 195 (2006), 1081–1085.
243. Charles, B., Davoren, P., Hague, W., McIntyre, D., Norris, R., Xiaonian, X., Metformin crosses the placenta: a modulator for fetal insulin resistance?. Br Med J 327:7420 (2004), 880–881.
244. Vanky, E., Zahlsen, K., Spigset, O., Carlsen, S.M., Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril 83 (2005), 1575–1578.
245. Cassina, M., Dona, M., Di Gianantonio, E., Litta, P., Clementi, M., First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. Hum Reprod Update 20 (2014), 656–669.
246. Gilbert, C., Valois, M., Koren, G., Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil steril 86 (2006), 658–663.
247. Gray, S.G., McGuire, T.M., Cohen, N., Little, P.J., The emerging role of metformin in gestational diabetes mellitus. Diabetes Obes Metab 19 (2017), 765–772.
248. Nestler, J.E., Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 358 (2008), 47–54.
249. Nicholson, W., Baptiste-Roberts, K., Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety. Best Pract Res Clin Obstet Gynaecol 25 (2011), 51–63.
250. Wouldes, T.A., Battin, M., Coat, S., Rush, E.C., Hague, W.M., Rowan, J.A., Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes. Arch Dis Child Fetal Neonatal Ed 101 (2016), F488–F493.
251. Rowan, J.A., Rush, E.C., Obolonkin, V., Battin, M., Wouldes, T., Hague, W.M., Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition at 2 years of age. Diabetes Care 34 (2011), 2279–2284.
252. Lautatzis, M.E., Goulis, D.G., Vrontakis, M., Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. Metabolism 62 (2013), 1522–1534.
253. Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R., Morris, A.D., Metformin and reduced risk of cancer in diabetic patients. BMJ 330 (2005), 1304–1305.
254. Libby, G., Donnelly, L.A., Donnan, P.T., Alessi, D.R., Morris, A.D., Evans, J.M., New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32 (2009), 1620–1625.
255. Gandini, S., Puntoni, M., Heckman-Stoddard, B.M., et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res 7 (2014), 867–885.
256. Mohammed, A., Janakiram, N.B., Brewer, M., et al. Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl Oncol 6 (2013), 649–659.
257. Anisimov, V.N., Berstein, L.M., Egormin, P.A., et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp gerontol 40 (2005), 685–693.
258. Anisimov, V.N., Do metformin a real anticarcinogen? A critical reappraisal of experimental data. Ann Transl Med, 2, 2014, 60.
259. Afzal, M., Kazmi, I., Gupta, G., Rahman, M., Kimothi, V., Anwar, F., Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats. Saudi Pharm J 20 (2012), 365–370.
260. Anisimov, V.N., Berstein, L.M., Popovich, I.G., et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging 3 (2011), 148–157.
261. Huang, X., Wullschleger, S., Shpiro, N., et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 412 (2008), 211–221.
262. Tajima, K., Nakamura, A., Shirakawa, J., et al. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice. Am J Physiol Endocrinol Metab 305 (2013), E987–E998.
263. Tomimoto, A., Endo, H., Sugiyama, M., et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 99 (2008), 2136–2141.
264. Vazquez-Martin, A., Lopez-Bonetc, E., Cufi, S., et al. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat 14 (2011), 212–223.
265. Cufi, S., Vazquez-Martin, A., Oliveras-Ferraros, C., Martin-Castillo, B., Joven, J., Menendez, J.A., Metformin against TGFbeta-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell cycle 9 (2010), 4461–4468.
266. Shackelford, D.B., Shaw, R.J., The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9 (2009), 563–575.
267. Green, A.S., Chapuis, N., Maciel, T.T., et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 116 (2010), 4262–4273.
268. Zakikhani, M., Dowling, R., Fantus, I.G., Sonenberg, N., Pollak, M., Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66 (2006), 10269–10273.
269. Lettieri Barbato, D., Vegliante, R., Desideri, E., Ciriolo, M.R., Managing lipid metabolism in proliferating cells: new perspective for metformin usage in cancer therapy. Biochimica et biophysica acta 1845 (2014), 317–324.
270. Jiralerspong, S., Palla, S.L., Giordano, S.H., et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27 (2009), 3297–3302.
271. Daugan, M., Dufay Wojcicki, A., d'Hayer, B., Boudy, V., Metformin: an anti-diabetic drug to fight cancer. Pharmacol Res 113 (2016), 675–685.
272. Sosnicki, S., Kapral, M., Weglarz, L., Molecular targets of metformin antitumor action. Pharmacol Rep 68 (2016), 918–925.
273. Lee, S.S., Lee, R.Y., Fraser, A.G., Kamath, R.S., Ahringer, J., Ruvkun, G., A systematic RNAi screen identifies a critical role for mitochondria in C elegans longevity. Nature Genet 33 (2003), 40–48.
274. Dillin, A., Hsu, A.L., Arantes-Oliveira, N., et al. Rates of behavior and aging specified by mitochondrial function during development. Science 298 (2002), 2398–2401.
275. Slack, C., Foley, A., Partridge, L., Activation of AMPK by the putative dietary restriction mimetic metformin is insufficient to extend lifespan in Drosophila. PloS One, 7, 2012, e47699.
276. Lopez-Otin, C., Galluzzi, L., Freije, J.M., Madeo, F., Kroemer, G., Metabolic control of longevity. Cell 166 (2016), 802–821.
277. Novelle, M.G., Ali, A., Dieguez, C., Bernier, M., de Cabo, R., Metformin: a hopeful promise in aging research. Cold Spring Harbor Perspect Med, 6, 2016, a025932.
278. Wu, L., Zhou, B., Oshiro-Rapley, N., et al. An ancient, unified mechanism for metformin growth inhibition in C elegans and cancer. Cell 167 (2016), 1705–1718.e13.